Paper Details

  1. Home
  2. Paper Details

Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.

Author: FerrarioJuan E, GershanikOscar S, LarramendyCelia, MurerMario G, SaboridoMariano D, TaraviniIrene R E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

D2 dopamine agonists are less prone to induce levodopa-induced dyskinesias than levodopa itself. This study found that pramipexole, a D2 agonist with a shorter half-life, was more likely to induce dyskinesias in rats pre-treated with levodopa. However, de novo treatment with D2 agonists was associated with a lower risk of dyskinesias.
Paper Details　
Original Abstract of the Article :
Levodopa-induced dyskinesias are one of the major limiting side effects encountered in the treatment of Parkinson's disease. Dopamine agonists of the D2 family are less prone to induce these abnormal involuntary movements (AIMs), and in some instances it has been proposed that they could counteract ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bbr.2008.06.021

データ提供：米国国立医学図書館（NLM）

Dopamine Agonists and Dyskinesias in Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that can significantly impact a person's motor function. This study investigates the effects of dopamine agonists, specifically cabergoline and pramipexole, on levodopa-induced dyskinesias, a common side effect of levodopa therapy. The researchers used an animal model of Parkinson's disease to compare the effects of these dopamine agonists on dyskinesias. The study's findings suggest that dopamine agonists, while less likely to induce dyskinesias than levodopa, may not be effective in modifying existing dyskinesias.

Dopamine Agonists: A Complex Role in Parkinson's Treatment

The study's findings suggest that dopamine agonists, while beneficial in treating Parkinson's disease, may not be effective in reversing existing dyskinesias induced by levodopa. The researchers found that prior levodopa therapy sensitized rats to the therapeutic effects of dopamine agonists, highlighting the complex interplay between these medications and the underlying disease process. The findings underscore the need for careful consideration of treatment strategies and potential side effects in Parkinson's disease.

Navigating the Desert of Parkinson's Treatment

Parkinson's disease is a challenging condition, and finding effective treatments is like navigating a vast and ever-shifting desert landscape. This study provides valuable insights into the potential role of dopamine agonists in Parkinson's treatment, highlighting both their potential benefits and limitations. The research emphasizes the need for careful consideration of treatment options and the importance of understanding the complex interplay between medications and the disease process.

Dr. Camel's Conclusion

This research reminds us that the path to treating Parkinson's disease is long and winding. Just as camels have adapted to survive in the desert, researchers are constantly seeking new ways to address the challenges posed by this complex neurodegenerative disorder. While dopamine agonists have a role to play, this study highlights the importance of ongoing research to develop more effective and safe therapies for Parkinson's disease.

Date :
  1. Date Completed 2009-01-15
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18638507

DOI: Digital Object Identifier

10.1016/j.bbr.2008.06.021

Related Literature

Article Analysis
・Side Effects of cabergoline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.